Cansino Biologics Inc. (688185.SH) Reports First-Half Results with Net Loss of 13.49 Million Yuan, Narrowing Year-over-Year

Stock News08-20

Cansino Biologics Inc. (688185.SH) released its 2025 interim report, showing operating revenue of 382 million yuan, representing a 26.00% year-over-year increase. The net loss attributable to shareholders was 13.4854 million yuan, narrowing compared to the same period last year. The net loss attributable to shareholders excluding non-recurring gains and losses was 85.9009 million yuan. Basic loss per share stood at 0.05 yuan. As the group's vaccine production capacity gradually increased and production capacity structure was further optimized, the group's comprehensive gross margin reached 82.54% during the reporting period, up 12.68 percentage points year-over-year. Meanwhile, the group continued to implement cost reduction and efficiency improvement measures, achieving cost savings across multiple expense categories during the reporting period.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment